Pacific Edge (ASX:PEB,NZE:PEB) said the US Centers for Medicare & Medicaid Services recommended a final "gapfill" price of $1,328.30 for the company's urine test Cxbladder Triage Plus, higher than the draft price of $1,018 proposed in April, according to a Wednesday filing with the Australian bourse.
The final price is expected to become effective from Jan.1, 2026, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.